von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura.
about
Pathophysiology of thrombotic thrombocytopenic purpuraCurrent concepts in thrombotic thrombocytopenic purpuraAnimal models for thrombotic thrombocytopenic purpuraRelationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse.Thrombotic thrombocytopenic purpura and its diagnosis.The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine.Splenectomy for the treatment of thrombotic thrombocytopenic purpura.Acquired thrombotic thrombocytopenic purpura as the presenting symptom of systemic lupus erythematosus. Successful treatment with plasma exchange and immunosuppression--report of two cases.Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura.ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura.Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation.Thrombotic thrombocytopenic purpura mimicking acute ischemic stroke.Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.Thrombotic thrombocytopenic purpura in advanced prostate cancer: case report and published work review.Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiencyADAMTS13 activity and the presence of acquired inhibitors in human immunodeficiency virus-related thrombotic thrombocytopenic purpura.Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura.Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: a single centre study.The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura.A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus.An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWFSepsis-induced disseminated intravascular coagulation with features of thrombotic thrombocytopenic purpura: a fatal fulminant syndrome.Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience.Thrombotic microangiopathy due to multiple autoantibodies related to antiphospholipid syndrome.Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura.Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura.Capnocytophaga canimorsus infection presenting with complete splenic infarction and thrombotic thrombocytopenic purpura: a case reportThrombotic thrombocytopenic purpura-what is new?ADAMTS13 content in plasma-derived factor VIII/von Willebrand factor concentrates.Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).Congenital thrombotic thrombocytopenic purpura with novel mutations in three unrelated Turkish children.Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research.Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.How I treat refractory thrombotic thrombocytopenic purpura.Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS-13 activity levels in inhibitor-treated rats by the use of defined doses of recombinant ADAMTS-13.High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence.ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model.ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro
P2860
Q24614117-19D17E09-5853-4C9E-B29E-79DE7068A182Q24656680-D44EF2CA-F2FF-4D3D-B3AD-DFF13B70C38CQ26851228-51D4A570-2D68-4CD1-A36B-C5B0EBEF558FQ33327295-D713528E-E34D-4021-BA5F-4C8B260F50FAQ33366296-49BC1575-B9F3-4EF3-B834-7A7B691DF88FQ33366493-EBD15328-AAB4-4120-957F-35D9C0A284F8Q33368032-046B482A-31EF-4BD7-9E67-8503A6499982Q33368709-90A099DB-922D-48AC-87E7-BE5AEDAA64D4Q33369692-6C411BA6-AF0D-4695-AE2F-66609D510D7EQ33371103-94557A66-128A-4DF5-ADE1-2F5D71FB725AQ33371965-04EF183A-E690-4B47-BA8A-CC4624843820Q33372320-B04D02C8-226B-4B9C-BE7A-E4F61247FA30Q33373912-19E1D4C4-04FE-4D05-B21F-BCE628F33352Q33374260-3977C9D5-BDFD-4465-9AFA-4B85295BF54EQ33376071-8CE32FF7-A55D-4CBE-8B25-862F14CAA4F6Q33376401-E815A5C2-D5A1-4D3D-8276-057C69C64EFEQ33377517-1E55019A-DF45-4E2D-99F6-23E26FFD5AACQ33380771-1657F335-8DA6-42AD-ABDE-C5C83BD41CB5Q33382390-5AB26BE7-F61E-4434-8966-0CAACF2199CBQ33382602-71372757-4071-4E01-AC91-0DD15931AA7CQ33383190-6E2A6BC4-FBC3-4B78-85EC-59B83F13946CQ33387616-8E693C97-7CD0-4111-9DF8-A19AFFBEDA44Q33388536-F920CD6F-85AB-419C-97C4-B6FBE92878B6Q33393950-D0A33B72-E586-46ED-9E1E-BB9FCA53263BQ33398993-14D0315F-CB3C-4B43-9FDD-77077D8992FCQ33400891-F8A2A8D7-D412-45AC-A627-387792920D53Q33401403-83880A1F-82F6-4DAE-AAF0-42D2B3664A86Q33401647-B3DDC978-46DC-4CDF-B344-08879804A676Q33404986-15D6312E-0658-407B-9D5D-707377706F7FQ33405965-A831905D-9DF1-42D0-A5B2-872255561F63Q33408786-D1C84E36-485E-4A90-8EFF-A75768D78A5CQ33410829-C68EDE8F-3A50-44E1-9815-14462CFDD3A0Q33410843-511D2B00-91C3-4E94-8421-9954C428A6E0Q33411009-BFC63487-6022-44A6-978A-7E73DC43B371Q33416588-17546EB8-5953-4A45-9EE1-280D6FDD0827Q33421268-7C5E057A-175A-4BF1-AF39-0AE35855AEBCQ33425638-F319C93F-B120-49F5-93A4-76491E61D618Q33427539-6B082A24-89B3-4E83-97F4-15604076DA84Q33431188-F5DD15FB-1ACD-4BCB-8E57-E1EE5B443DBFQ33431193-60B7AF6C-28CA-4F98-9B7F-0D549466873B
P2860
von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura.
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
von Willebrand factor cleaving ...... otic thrombocytopenic purpura.
@ast
von Willebrand factor cleaving ...... otic thrombocytopenic purpura.
@en
type
label
von Willebrand factor cleaving ...... otic thrombocytopenic purpura.
@ast
von Willebrand factor cleaving ...... otic thrombocytopenic purpura.
@en
prefLabel
von Willebrand factor cleaving ...... otic thrombocytopenic purpura.
@ast
von Willebrand factor cleaving ...... otic thrombocytopenic purpura.
@en
P2093
P2860
P1476
von Willebrand factor cleaving ...... otic thrombocytopenic purpura.
@en
P2093
Maria Teresa Canciani
Silvia Ferrari
Silvia Lavoretano
P2860
P304
P356
10.1111/J.1365-2141.2004.05217.X
P407
P577
2004-11-01T00:00:00Z